Insider Selling: ANI Pharmaceuticals Inc (NASDAQ:ANIP) Major Shareholder Sells 7,579 Shares of Stock

ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $68.21, for a total value of $516,963.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Meridian Venture Partners Ii L also recently made the following trade(s):

  • On Thursday, August 15th, Meridian Venture Partners Ii L sold 9,315 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $69.34, for a total value of $645,902.10.
  • On Friday, August 9th, Meridian Venture Partners Ii L sold 19,860 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.70, for a total value of $1,423,962.00.
  • On Tuesday, August 13th, Meridian Venture Partners Ii L sold 61,697 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.64, for a total value of $4,419,973.08.

ANI Pharmaceuticals stock traded down $0.56 during mid-day trading on Thursday, reaching $66.51. 843 shares of the company were exchanged, compared to its average volume of 168,514. The business has a fifty day moving average of $78.75 and a 200 day moving average of $70.69. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The firm has a market cap of $816.96 million, a P/E ratio of 14.40 and a beta of 2.17. ANI Pharmaceuticals Inc has a 12-month low of $36.92 and a 12-month high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.26. The company had revenue of $54.36 million during the quarter, compared to analyst estimates of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. ANI Pharmaceuticals’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.13 earnings per share. Sell-side analysts predict that ANI Pharmaceuticals Inc will post 5.29 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. First Trust Advisors LP lifted its holdings in shares of ANI Pharmaceuticals by 1.2% during the 1st quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock valued at $1,067,000 after purchasing an additional 179 shares during the last quarter. Texas Permanent School Fund lifted its holdings in shares of ANI Pharmaceuticals by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 5,633 shares of the specialty pharmaceutical company’s stock valued at $397,000 after purchasing an additional 206 shares during the last quarter. Comerica Bank lifted its holdings in shares of ANI Pharmaceuticals by 3.1% during the 1st quarter. Comerica Bank now owns 8,239 shares of the specialty pharmaceutical company’s stock valued at $570,000 after purchasing an additional 248 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 13,070 shares of the specialty pharmaceutical company’s stock valued at $1,074,000 after purchasing an additional 273 shares during the last quarter. Finally, THB Asset Management lifted its holdings in shares of ANI Pharmaceuticals by 1.1% during the 1st quarter. THB Asset Management now owns 25,431 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 67.00% of the company’s stock.

Several brokerages recently issued reports on ANIP. Canaccord Genuity reissued a “buy” rating and issued a $90.00 price objective (up previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. BidaskClub cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 13th. ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Cantor Fitzgerald restated a “buy” rating and set a $89.00 target price on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $89.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Article: How does a security become overbought?

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.